Phase 3 Bipolar Disorder Trial, Recruiting NCT04777357 Sponsor: AbbVie Condition: Bipolar Disorder
Back to Bipolar Disorder

Phase 3 Bipolar Disorder Trial, Recruiting

NCT04777357
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been officially diagnosed with Bipolar I Disorder (confirmed using a specific structured interview tool used with children and adolescents).
  • Your current depressive episode (period of low mood) has been going on for more than 2 weeks but less than 12 months.
  • You have had at least one manic episode (a period of unusually high or irritable mood) at some point in your life.
  • Your depression symptoms score at or above a certain level on a standard rating scale at two separate visits (confirm with trial site).
  • Your manic symptoms score at or below a certain level on a standard rating scale at two separate visits, meaning mania is not currently severe (confirm with trial site).
  • Your overall illness is rated as at least "moderately ill" by a clinician at two separate visits.

Who may not be able to join:

  • You have a diagnosis of schizophrenia, schizoaffective disorder, PTSD, antisocial personality disorder, borderline personality disorder, or certain other mental health conditions.
  • You have had a diagnosis of a substance use disorder (not including caffeine or tobacco) within the 3 months before the first screening visit.
  • You have a history of a serious reaction called serotonin syndrome or neuroleptic malignant syndrome (confirm with trial site).
  • You have had four or more mood episodes within the 12 months before the first visit.
  • You have a diagnosis of intellectual disability (IQ below 70), autism spectrum disorder, or a chromosomal condition that affects development.
  • You have a history of seizures, unless they were only fever-related seizures in childhood.
  • You have had a significant head injury, a brain tumour, or another condition that increases the risk of seizures.
  • You currently need to take certain medications that affect how the body processes drugs (called CYP3A4 inhibitors or inducers — confirm with trial site).
  • You currently need to take any psychiatric medication or other medication, supplement, or herbal product that affects the mind or mood.
  • You have received a long-acting injectable antipsychotic medication within a recent period before screening (confirm with trial site).
  • You have taken a medication called clozapine at a dose of 50 mg per day or more within the past 2 years.
  • You have a history of or currently have any eye condition, such as glaucoma, cataracts, retinal detachment, or eye surgery or trauma — except for simple vision/refractive problems like short-sightedness.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: ABBVIE INC., AbbVie

Phone: 844-663-3742

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Registry
ClinicalTrials.gov
Start date
28 April 2021
Est. completion
1 March 2027

Where this trial is recruiting

Puerto Rico 🇷🇺 Russia 🇺🇸 United States

Primary endpoints

Number of Participants with Adverse Events; Abnormal Change from Baseline in Vital Signs; Number of Participants with Incidence of Abnormal Clinical Laboratory Test Results; Change in Electrocardiogram (ECG); Change From Baseline in Simpson-Angus Scale (SAS); Change from Baseline in Columbia-Suicide Severity Rating Scale (C-SSRS); Change From Baseline in Barnes Akathisia Rating Scale (BARS); Change From Baseline in Abnormal Involuntary Movement Scale (AIMS); Change in Children's Depression Rating Scale - Revised (CDRS-R) Total Score

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov